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Accepted 5 November 2012A primigravid woman 35 years of age was referred to the
hospital for genetic counseling in the second trimester because
of advanced maternal age and a positive family history of type
IV osteogenesis imperfecta (OI). The woman had a body
weight of 56 kg and a height of 145 cm, and her husband had
a height of 168 cm. Her husband had normal sclerae, normal
stature, dentinogenesis imperfecta, and osteopenia, and he had
sustained mild fractures with trauma since childhood. The
husband, his 13-year-old daughter (151 cm in height) from
a previous marriage, his mother (150 cm in height), and his
aunt also had type IV OI. His daughter had multiple fractures
of the long bones that required long-term bisphosphonate
treatment. Molecular analysis of the husband and his affected
family members revealed a G to A change at position c.2279
(c.2279 G > A, GGA > GAA) of the exon 37 in the COL1A2
gene leading to a change of glycine at codon 760 to glutamic
acid (G760E). Prenatal ultrasonographic examination at 19
weeks of gestation revealed a fetus with no skeletal abnor-
malities and a biparietal diameter (BPD), an abdominal cir-
cumference (AC), and a femur length (FL) equivalent to 19
weeks. The woman underwent amniocentesis at 19 weeks of* Corresponding author. Department of Obstetrics and Gynecology, Mackay
Memorial Hospital, 92, Section 2, Chung-Shan North Road, Taipei, Taiwan.
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46,XX. Molecular analysis of uncultured amniocytes revealed
a missense mutation of c.2279 G > A, pG760E in COL1A2
(Fig. 1). After genetic counseling of possible phenotypic
variability in OI with the parents, the mother elected to carry
the pregnancy to term. Prenatal ultrasonography in the third
trimester showed shortening of the long bones. At 37 weeks of
gestation, fetal ultrasonography showed a BPD of 9.09 cm (36
weeks), an AC of 32.6 cm (38 weeks), a FL of 6.36 cm (33
weeks), a tibia length of 6.0 cm (34 weeks), a fibula length of
5.4 cm (34 weeks), and a humerus length of 5.53 cm (33
weeks). A cesarean section was performed at 39 weeks of
gestation, and a 3120-g female baby was delivered with a body
length of 48 cm (15e50th percentile). Postnatal radiography
showed neither curvature nor fracture of the long bones. She
was doing well with no fractures at the age of 1 month.
OI is a genetic disorder of defective collagen synthesis
characterized by increased bone fragility, osteopenia, blue
sclerae, ligamental and dermal hyperlaxity, dentinogenesis
imperfecta, and hearing loss [1,2]. The occurrence of OI in
newborns has been estimated to be between one in 20,000
births and one in 60,000 births [3,4]. About 90% of the OI
patients have autosomal dominant mutations in the COL1A1
gene (OMIM 120150) encoding a1 type 1 collagen chain and
in the COL1A2 gene (OMIM 120160) encoding a2 type 1
collagen chain [5]. Type I OI is associated with mutations incs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
Fig. 1. Molecular analysis of the fetus and the father shows a heterozygous G
to A change at position c.2279 (c.2279G > A, GGA/ GAA) of the exon 37
in the COL1A2 gene leading to a change of glycine at codon 760 to glutamic
acid (G760E).
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stop codon due to deletions, duplications, nonsense mutations,
or frameshift mutations, and types II, III, and IV OI are
associated with mutations in either COL1A1 or COL1A2
mostly caused by glycine substitutions and less frequently
caused by splicing defects, deletions, insertions, or duplica-
tions [6e11].
We have presented a novel OI mutation in a Chinese family
with a dominant inherited form of type IV OI resulting from
a heterozygous mutation in COL1A2. The present case pro-
vides evidence that a glycine substitution by glutamic acid at
codon 2279 can result in type IV OI but no a lethal outcome.
The substitution of an amino acid for a glycine in the repeating
Gly-Xamino acid-Yamino acid triplet repeats in the triple helical
domains of the type 1 collagen chains can delay triple-helix
formation, permit prolonged access of modifying enzymes,
and decrease the thermal stability of the protein [12]. In
a study of 290 individual mutations that resulted in sub-
stitutions of glycine residues in COL1A2 affecting the a2(I)
chain, Marini et al [5] found that about one-fifth (18.9%) (55/
290) of all independent glycine substitutions in a2(I) resulted
in perinatal lethal type II OI. In their study, substitutions of
glycine in a2(I) chains by serine (44%, or 128/290), aspartic
acid (15.8%, or 46/290), tryptophan (13.9%, or 40/290), and
arginine (10.3%, or 30/290), resulting from mutations in the
first position of glycine codons accounted for most of all a2(I)
substitutions, and the substitution of glycine by glutamic acid
accounted for only 4.9% (14/290) of the cases. Marini et al [5]also found that substitutions of glycine by glutamic acid,
aspartic acid, cysteine and arginine had a lethal outcome more
often than average for a2(I) chain. The lethal outcomes were
in the order of glutamic acid (42.9%, or 6/14), aspartic acid
(32.6%, or 15/46), cysteine (24%, or 6/25), and arginine
(23.3%, or 7/30). Our case represents a rare occasion and adds
Gly760Glu to the list of the substitution of glycine by glutamic
acid in the a2(I) chain with a nonlethal form of OI and
a favorable outcome.Acknowledgments
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